recent articles
Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have...
© 2023 Tissuepathology.com. All rights reserved. Millennial Consulting. | Web Design by Zealth Digital Marketing